Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 10:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 586 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Test solution Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy of Different Oral Rehydration Solutions on the Hydration Status of Healthy Males

NCT05428774
View directory record Official record
Conditions
Fluid Retention, Beverage Hydration Index, Hydration Status
Interventions
Test product 1, Test product 2, Placebo
Other
Lead sponsor
Liquid I.V.
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Oct 22, 2026, 10:51 AM EDT
Recruiting Phase 1 Interventional

A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors

NCT06357377
View directory record Official record
Conditions
Pediatric Tumor of CNS, Pediatric Tumor of Brain, Diffuse Midline Glioma, H3 K27M-Mutant, Pediatric Tumor of Brain Stem, Pineocytoma, Choroid Plexus Carcinoma, Childhood, Spinal Cord Tumor, High Grade Glioma
Interventions
NEO100
Drug
Lead sponsor
Neonc Technologies, Inc.
Industry
Eligibility
5 Years to 18 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 22, 2026, 10:51 AM EDT
Active, not recruiting Phase 3 Interventional

Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency

NCT05345171
View directory record Official record
Conditions
OTC Deficiency
Interventions
DTX301, Placebo, Oral Corticosteroids, Placebo for oral corticosteroids, Sodium Acetate
Genetic · Other · Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
12 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
4
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 22, 2026, 10:51 AM EDT
Completed Phase 2 Interventional Results available

Candin Safety & Efficacy Study for the Treatment of Warts

NCT01757392
View directory record Official record
Conditions
Warts, Human Papilloma Virus
Interventions
Candida albicans Skin Test Antigen
Biological
Lead sponsor
Nielsen BioSciences, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Fort Smith, Arkansas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Oct 22, 2026, 10:51 AM EDT
Active, not recruiting Not applicable Interventional

Effectiveness of PGx Testing

NCT04120480
View directory record Official record
Conditions
Polypharmacy
Interventions
Pharmacogenomic test
Diagnostic Test
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years to 79 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 2, 2024 · Synced Oct 22, 2026, 10:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinical Evaluation of 3 Contact Lens Materials With 3 Solution Types

NCT03466060
View directory record Official record
Conditions
Visual Acuity, Slit Lamp Biomicroscopy (Corneal Staining Assessment)
Interventions
Opti-Free : RevitaLens / Clear Care : RevitaLens, Opti-Free : RevitaLens / RevitaLens : Clear Care, Clear Care : RevitaLens/ Opti-Free : RevitaLens, Clear Care : RevitaLens / RevitaLens : Opti-Free, RevitaLens : Clear Care/ Opti-Free : RevitaLens, RevitaLens : Clear Care / RevitaLens : Opti-Free, RevitaLens : Opti-Free / Clear Care : RevitaLens, RevitaLens : Opit-Free / RevitaLens : Clear Care
Device
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Eligibility
18 Years to 69 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
5
States / cities
Anaheim, California • Berkeley, California • Jacksonville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 22, 2026, 10:51 AM EDT
Not listed Phase 2 Interventional

A Study to Assess the Effect of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Uncontrolled Advanced Glaucoma With Prior Failed Trabeculectomy or Tube Shunt

NCT02173223
View directory record Official record
Conditions
Advanced Glaucoma
Interventions
Rho-Kinase Inhibitor
Drug
Lead sponsor
New York Glaucoma Research Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2015 · Synced Oct 22, 2026, 10:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Galcanezumab in Healthy Participants.

NCT02836613
View directory record Official record
Conditions
Healthy
Interventions
Galcanezumab
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
3
States / cities
Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Oct 22, 2026, 10:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

One-month Clinical Evaluation of Oté Sensation Multi-Purpose Solution Care System

NCT03278223
View directory record Official record
Conditions
Myopia, Hyperopia
Interventions
Test solution, Control solution
Device
Lead sponsor
OTE North America
Industry
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
5
States / cities
Sarasota, Florida • Pittsburg, Kansas • Vestal, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2021 · Synced Oct 22, 2026, 10:51 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

The Sequestration of Holistic Stress Management Techniques for Adults

NCT06098755
View directory record Official record
Conditions
Stress, Job, PTSD, Hypervigilance, Hyperthyroidism, Migraine, Migraine With Aura, Immunodeficiency, Sickle Cell Trait, Sickle Cell Disease, Anemia, Sickle Cell, Anemia, Fatigue, Anxiety, Depression, Flat Feet, Lordosis, TBI (Traumatic Brain Injury), Rheumatoid Arthritis, Arthritis, Masturbation, Priapism, Erectile Dysfunction, Flight Reaction, Hypertension, Sexual Arousal Disorder, Hemorrhoids, Fibroid
Interventions
Holistic Medicine (HM)
Behavioral
Lead sponsor
Goddess Zena I. Jones
Other
Eligibility
22 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Anchorage, Alaska
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 22, 2026, 10:51 AM EDT
Recruiting Phase 1 Interventional

Gut Permeability and Microbiome in Preterm Infants

NCT07667049
View directory record Official record
Conditions
Prematurity Complications
Interventions
measurement of intestinal permeability
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
Up to 4 Days
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 22, 2026, 10:51 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032

NCT04086121
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Spesolimab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Scottsdale, Arizona • Fort Myers, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 22, 2026, 10:51 AM EDT
Terminated Phase 3 Interventional

Study to Investigate the Effect of Aprotinin of Transfusion Requirements in Patients Undergoing Surgical Procedures for Lung or Esophageal Cancer

NCT00306137
View directory record Official record
Conditions
Blood Loss, Surgical
Interventions
Trasylol (Aprotinin, BAYA0128), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
12
States / cities
Atlanta, Georgia • Augusta, Georgia • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2014 · Synced Oct 22, 2026, 10:51 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety of Intravenous Acetaminophen Vs Placebo for the Treatment of Endotoxin-Induced Fever in Healthy Adult Males

NCT00493311
View directory record Official record
Conditions
Fever
Interventions
IV Placebo, IV Acetaminophen, Reference Standard Endotoxin (RSE)
Drug · Biological
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2016 · Synced Oct 22, 2026, 10:51 AM EDT
Terminated Phase 3 Interventional Results available

LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye

NCT03711929
View directory record Official record
Conditions
Non Infectious Uveitis
Interventions
DE-109 Intravitreal Injections, Sham Procedure, DE-109 Intravitreal Injections (Open Label)
Drug · Other
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
38
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Oct 22, 2026, 10:51 AM EDT
Not listed Not applicable Interventional

Auricular Acupuncture vs SOC in Migraine HA

NCT02681211
View directory record Official record
Conditions
Migraine Headache
Interventions
Auricular Acupuncture, Ketorolac 0.5mg/kg, max 30mg, Metoclopramide 0.1 mg/kg, max 10mg, Diphenhydramine 1mg/kg, max 50mg, Normal saline fluid bolus 20mL/kg, max 1000mL
Other · Drug
Lead sponsor
University of Louisville
Other
Eligibility
8 Years to 18 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
2
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 22, 2026, 10:51 AM EDT
Completed Phase 4 Interventional Results available

Olfactory Deficits in MCI as Predictor of Improved Cognition on Donepezil

NCT01845636
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Donepezil, Atropine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
55 Years to 95 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Oct 22, 2026, 10:51 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of Mirikizumab Solution (LY3074828) in Healthy Participants

NCT07446101
View directory record Official record
Conditions
Healthy
Interventions
Mirikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
5
States / cities
Daytona Beach, Florida • Dilworth, Minnesota • Dallas, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 22, 2026, 10:51 AM EDT
Recruiting No phase listed Observational

Long-term Impact of Infection With Novel Coronavirus (COVID-19)

NCT04362150
View directory record Official record
Conditions
COVID
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 100 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 22, 2026, 10:51 AM EDT
Completed Phase 3 Interventional Results available

Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)

NCT01979952
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Matching Placebo, Nintedanib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
11
States / cities
Danbury, Connecticut • Sarasota, Florida • Skokie, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 22, 2026, 10:51 AM EDT
Recruiting Not applicable Interventional

Screening Women With Prior HPV for Anal Neoplasia

NCT05217940
View directory record Official record
Conditions
HPV-related Lower Genital Tract Neoplasias, HPV-related Anal Neoplasias, Early Stage Lower Genital Tract Cancers
Interventions
Diagnostic tests for anal cancer screening
Diagnostic Test
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
35 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
New York, New York • Charleston, South Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 22, 2026, 10:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of Single Ascending Doses of PUL-042 Inhalation Solution in Healthy Subjects

NCT02124278
View directory record Official record
Conditions
Healthy
Interventions
PUL-042 Inhalation Solution
Drug
Lead sponsor
Pulmotect, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Oct 22, 2026, 10:51 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Linus Health CDS Retrospective Validation Study

NCT05900310
View directory record Official record
Conditions
Cognitive Impairment, Motor Disorders, Dementia
Interventions
Core Cognitive Evaluation (CCE)
Diagnostic Test
Lead sponsor
Linus Health, Inc.
Industry
Eligibility
55 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Oct 22, 2026, 10:51 AM EDT
Completed Not applicable Interventional

CT Guided CI Programming

NCT04506424
View directory record Official record
Conditions
Cochlear Implants, Hearing Loss, Amusia
Interventions
CT Guided Cochlear Implant Programming
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Oct 22, 2026, 10:51 AM EDT